October 29, 2025 — Leads & Copy — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) announced its financial results for the third quarter ended September 30, 2025.
Total net sales for the third quarter were $653.0 million, a 0.5 percent increase compared to $649.7 million in Q3 2024. On a currency-neutral basis, quarterly sales decreased 1.7 percent due to lower sales in both Life Science and Clinical Diagnostics segments.
Life Science Group net sales were $261.8 million, up 0.3 percent from 2024. Clinical Diagnostics Group net sales were $391.2 million, an increase of 0.6% compared to the same period in 2024.
The company recognized a change in the fair market value of its investment in Sartorius AG, contributing to a net loss of $(341.9) million, or $(12.70) per share. Non-GAAP net income was $60.8 million, or $2.26 per share, compared to $56.3 million, or $2.02 per share, in 2024.
Bio-Rad maintains its financial outlook for 2025, expecting non-GAAP, currency-neutral revenue growth of 0 to 1.0 percent and a non-GAAP operating margin of approximately 12.0 to 13.0 percent.
Management will discuss results in a conference call at 2 PM Pacific Time on October 29, 2025. A live webcast will be available on the company’s website.
Norman Schwartz, Bio-Rad’s Chairman and CEO, stated the teams delivered solid results in Q3.
Source: Bio-Rad Laboratories, Inc.
